COMPANY

Senhwa Biosciences

Profile checked Oct 10, 2026

Keywords: Community-acquired Pneumonia SARS-CoV-2 -Associated Pneumonia Influenza With Pneumonia Basal Cell Carcinoma COVID-19 Covid19 Cholangiocarcinoma CX-4945 CX-5461

6Trials (company is sponsor)

Timeline

Mar 20, 2024 Trial start Phase 2: CX-4945 in Viral Community Acquired Pneumonia source ↗
Nov 28, 2022 Trial start Phase 1: A Study of Silmitasertib (CX-4945) in Healthy Subject source ↗
Sep 8, 2021 Trial start Phase 1: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation source ↗
Nov 30, 2020 Trial start Phase 2: Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 source ↗
Apr 16, 2019 Trial start Phase 1: Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) source ↗
2014-06 Trial start Phase 1/Phase 2: Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Phase 1 · Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation · NCT04890613

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT04890613	Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	Phase 1	Recruiting	Sep 8, 2021	2027-03 (estimated)
NCT06202521	CX-4945 in Viral Community Acquired Pneumonia	Phase 2	Terminated	Mar 20, 2024	Apr 22, 2025 (actual)
NCT03897036	Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	Phase 1	Completed	Apr 16, 2019	Jan 25, 2024 (actual)
NCT05817708	A Study of Silmitasertib (CX-4945) in Healthy Subject	Phase 1	Completed	Nov 28, 2022	Mar 23, 2023 (actual)
NCT04663737	Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	Phase 2	Completed	Nov 30, 2020	Aug 16, 2021 (actual)
NCT02128282	Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma	Phase 1/Phase 2	Completed	2014-06	Nov 6, 2020 (actual)